Chennan Li

Chennan Li

Auto-generated profile, based on publicly available information

Chennan Li

National Cancer Institute 3 Genitourinary Malignancies Branch Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
APArpita S. Pal
Arpita S. Pal
AAAlejandra Agredo
Alejandra Agredo
NLNadia A. Lanman
Nadia A. Lanman
JSJihye Son
Jihye Son
ISIkjot Singh Sohal
Ikjot Singh Sohal
AKAndrea Kasinski
Andrea Kasinski
EGFR inhibitors (EGFRi) are standard-of-care treatments administered to patients with non–small cell lung cancer (NSCLC) that harbor EGFR alterations. However, development of resistance posttreatment remains a major challenge. Multiple mechanisms can promote survival of EGFRi-treated NSCLC cells, including secondary mutations in EGFR and activation of bypass tracks that circumvent the requirement for EGFR signaling. Nevertheless, the mechanisms involved in bypass signaling activation are understudied and require further elucidation. In this study, we identify that loss of an epigenetic factor, lysine methyltransferase 5C (KMT5C), drives resistance of NSCLC to multiple EGFRis, including erlotinib, gefitinib, afatinib, and osimertinib. KMT5C catalyzed trimethylation of histone H4 lysine 20 (H4K20), a modification required for gene repression and maintenance of heterochromatin. Loss of KMT5C led to upregulation of an oncogenic long noncoding RNA, LINC01510, that promoted transcription of the oncogene MET, a component of a major bypass mechanism involved in EGFRi resistance. These findings underscore the loss of KMT5C as a critical event in driving EGFRi resistance by promoting a LINC01510/MET axis, providing mechanistic insights that could help improve NSCLC treatment. Significance: Dysregulation of the epigenetic modifier KMT5C can drive MET-mediated EGFRi resistance, implicating KMT5C loss as a putative biomarker of resistance and H4K20 methylation as a potential target in EGFRi-resistant lung cancer.

11 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SWScott Wilkinson
Scott Wilkinson
AKAnson T. Ku
Anson T. Ku
RLRosina T. Lis
Rosina T. Lis
IKIsaiah M. King
Isaiah M. King
DLDaniel Low
Daniel Low
ASAdam G. Sowalsky
Adam G. Sowalsky
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to definitive treatment. Sufficient profiling of baseline disease has remained a challenge in enabling the in-depth assessment of phenotypes associated with exceptional vs. poor pathologic responses after treatment. In this study, we report comprehensive and integrative gene expression profiling of 37 locally advanced prostate tumors prior to six months of androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide prior to radical prostatectomy. A robust transcriptional program associated with HER2 activity was positively associated with poor outcome and opposed AR activity, even after adjusting for common genomic alterations in prostate cancer including PTEN loss and expression of the TMPRSS2:ERG fusion. Patients experiencing exceptional pathologic responses demonstrated lower levels of HER2 and phospho-HER2 by immunohistochemistry of biopsy tissues. The inverse correlation of AR and HER2 activity was found to be a universal feature of all aggressive prostate tumors, validated by transcriptional profiling an external cohort of 121 patients and immunostaining of tumors from 84 additional patients. Importantly, the AR activity-low, HER2 activity-high cells that resist ADT are a pre-existing subset of cells that can be targeted by HER2 inhibition alone or in combination with enzalutamide. In summary, we show that prostate tumors adopt an AR activity-low prior to antiandrogen exposure that can be exploited by treatment with HER2 inhibitors. ClinicalTrials.gov registration: NCT02430480 .

13 January 2026 in Cancer Research
Verified
Journal Article
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Reprogramming of the androgen receptor (AR) cistrome is associated with prostate cancer progression, and advanced castration-resistant prostate cancers (CRPC) tend to rely on reprogrammed/noncanonical AR signaling that remains active under treatment with AR signaling inhibitors (ARSI). In this study, we identified ecotropic viral integration site 1 (EVI1), an oncogenic nuclear transcription factor (TF) encoded by MECOM, as an AR-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus. MECOM depletion in prostate cancer cells decreased proliferation, altered cell survival transcriptional programs, and reduced the number of super-enhancers (SE), leading to a dynamic change in the SE landscape and a decrease in the expression of SE-regulated oncogenic TFs, along with increased proapoptotic signatures. Notably, cells overexpressing MECOM and its protein, EVI1, were susceptible to PARP inhibitors (PARPi) regardless of their DNA damage response or homologous recombination repair (HRR) gene mutation status. These insights reveal the crucial role of EVI1 in regulating cell survival within the context of an AR-reprogrammed chromatin landscape. More importantly, the findings suggest that MECOM overexpression may be another biomarker that could significantly broaden the use of PARPis beyond those with HRR gene mutations. Significance: MECOM is a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer that promotes susceptibility to PARP inhibition, positioning MECOM as a biomarker in patients without homologous recombination repair gene mutations.

9 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CLChennan Li
Chennan Li
JYJuanJuan Yin
JuanJuan Yin
MAMelissa L. Abel
Melissa L. Abel
DSDana S. Vargas Solivan
Dana S. Vargas Solivan
KBKinjal Bhadresha
Kinjal Bhadresha
ASAdam G. Sowalsky
Adam G. Sowalsky
Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of PTEN, TP53, RB1 and BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC50: 0.27 μM) and the MCL-1 inhibitor AZD-5991 (IC50: 0.060 μM). Overall, NCI&-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Enriched Pathways from genes closest to AR_unique sites

17 June 2026
Verified
Other
Open access
PDF file
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
MECOM suppression enhances spheroid inhibition and apoptosis